Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCP versus methergine for retained products of conception after abortion
IRCT20220430054708N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of ethinyl estradiol + desogestrel, methylergometrine, doxycycline and misoprostol in retained placenta (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Incidence of infection, Gastrointestinal symptoms and 1 more. Started Jun 2022; status: completed.
02
Drugs
ethinyl estradiol + desogestrelmethylergometrinedoxycyclinemisoprostol
03
Conditions
retained placenta
Beyond the preview
Go deeper on IRCT20220430054708N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220430054708N1.